BTK and breast cancer: The efficiency of ibrutinib in these cancers has already been proposed in previous publications [19, 29, 30], and we indeed found ibrutinib to be the most potent BTK inhibitor of ERBB signalling in breast cancer cell lines, once again confirming its anticancer effects.